Drug Trial Radar · NCT05405166
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
531
Actual
Start
Jun 23, 2022
Primary completion
Nov 6, 2024
Study completion Oct 22, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who will receive at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants were randomized 1:1 into 1 of 2 study arms: Arm SC: Isatuximab SC + Pd Arm IV: Isatuximab IV + Pd Participants are allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.
Conditions
- Plasma Cell Myeloma Recurrent
Interventions
Isatuximab IVDrug
Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
Isatuximab SCDrug
Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
DexamethasoneDrug
Pharmaceutical form: Tablet; Route of administration: Oral
PomalidomideDrug
Pharmaceutical form: hard capsules; Route of administration: Oral
DexamethasoneDrug
Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
MontelukastDrug
Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
Paracetamol / AcetaminophenDrug
Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
DiphenhydramineDrug
Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
MethylprednisoloneDrug
Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
- Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady StateTime frame: Pre-dose at Cycle 6 Day 1
Locations
128 sites in 21 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers - Aurora- Site Number : 8400021
Aurora, Colorado
Mayo Clinic in Florida- Site Number : 8400008
Jacksonville, Florida
Boca Raton Clinical Research Associates- Site Number : 8400030
Plantation, Florida
Hattiesburg Clinic- Site Number : 8400006
Hattiesburg, Mississippi
Atlantic Health System- Site Number : 8400005
Morristown, New Jersey
New York Oncology Hematology - Albany Cancer Center- Site Number : 8400017
Albany, New York
Novant Health Neurology & Sleep- Site Number : 8400014
Charlotte, North Carolina
Gabrail Cancer Center- Site Number : 8400027
Canton, Ohio
Oncology Hematology Care - Fairfield- Site Number : 8400016
Fairfield, Ohio
Spartanburg Regional Medical Center- Site Number : 8400002
Spartanburg, South Carolina
University of Texas - Southwestern Medical Center- Site Number : 8400024
Dallas, Texas
Texas Oncology - San Antonio Medical Center - Research Drive- Site Number : 8400020
San Antonio, Texas
Veterans Affairs Medical Center - Salt Lake City- Site Number : 8400011
Salt Lake City, Utah
Investigational Site Number : 0320008
Buenos Aires, Argentina
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320007
Buenos Aires, Argentina
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0320004
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320005
Buenos Aires, Argentina
Investigational Site Number : 0320010
Córdoba, Argentina
Investigational Site Number : 0320009
Mendoza, Argentina
Investigational Site Number : 0320006
La Plata, Buenos Aires, Argentina
Investigational Site Number : 0360007
Liverpool, New South Wales, Australia
Investigational Site Number : 0360004
Waratah, New South Wales, Australia
Investigational Site Number : 0360003
Wollongong, New South Wales, Australia
Investigational Site Number : 0360008
Adelaide, South Australia, Australia
Investigational Site Number : 0360006
Melbourne, Victoria, Australia
Investigational Site Number : 0360009
Melbourne, Victoria, Australia
Investigational Site Number : 0360001
Richmond, Victoria, Australia
Instituto Americas - Ensino, Pesquisa e Inovação - Rio de Janeiro - Avenida Jorge Curi- Site Number : 0760004
Rio de Janeiro, Brazil
Clinica São Germano- Site Number : 0760001
São Paulo, Brazil
Núcleo de Oncologia e Hematologia do Ceará- Site Number : 0760006
Fortaleza, Ceará, Brazil
MultiHemo - Recife - Rua Padre Carapuceiro- Site Number : 0760007
Recife, Pernambuco, Brazil
CHN - Complexo Hospitalar de Niterói- Site Number : 0760008
Niterói, Rio de Janeiro, Brazil
Hospital Mae de Deus- Site Number : 0760003
Porto Alegre, Rio Grande do Sul, Brazil
Investigational Site Number : 1240001
Toronto, Ontario, Canada
Investigational Site Number : 1240004
Greenfield Park, Quebec, Canada
Investigational Site Number : 1240003
Montreal, Quebec, Canada
Investigational Site Number : 1520001
Temuco, La Araucanía, Chile
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.